Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Program Bridges Gap to Develop New Therapeutics

Published: Wednesday, December 18, 2013
Last Updated: Tuesday, December 17, 2013
Bookmark and Share
New projects advance treatments for acute radiation syndrome, brain injury from cardiac arrest and a rare blood disorder.

The National Institutes of Health has launched three pre-clinical projects to advance potential new treatments for acute radiation syndrome, brain injury following cardiac arrest and a rare blood disorder called beta thalassemia.

The projects are part of the Bridging Interventional Development Gaps (BrIDGs) program, which is funded by the NIH Common Fund and led by NIH's National Center for Advancing Translational Sciences (NCATS).

BrIDGs provides eligible scientists with no-cost access to contractor services, such as toxicology studies, for pre-clinical therapeutic development. To be eligible for the program, projects must have been effective in a disease model.

Researchers often apply to BrIDGs because they have hit a roadblock and need additional expertise or lack other resources. Rather than funding successful applicants directly, BrIDGs supports expert NIH contractors who perform pre-clinical services for the researchers free-of-charge.

"BrIDGs researchers and partner scientists work together to bridge the gap between a basic discovery and clinical testing, thereby ensuring potential treatments have a chance to reach patients who need them," said Christopher P. Austin, M.D., NCATS director.

A primary goal of a BrIDGs project is the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin human clinical trials. To date, BrIDGs scientists have generated data to support 12 INDs submitted to the FDA, as well as one clinical trial application to Health Canada. They also have evaluated 12 of the 13 projects in clinical trials.

Three BrIDGs-supported therapeutic agents have gone as far as Phase II clinical trials, in which researchers provide an experimental therapy to a group of patients to evaluate its safety and effectiveness. Third-party investors have licensed seven compounds during or after their development through the BrIDGs program.

BrIDGs scientists selected the following new projects from the 2013 application solicitation:

Acute Radiation Syndrome
Manufacturing of RLIP76-LyoPL for Acute Radiation Syndrome Henry Hebel, M.B.A., vice president of drug development Terapio Corp., Austin, Texas

Exposure to radiation, whether from a compromised nuclear reactor or a radiation weapon, can lead to acute radiation syndrome, a life-threatening multi-organ illness. Currently, there is no FDA-approved treatment for the syndrome. This project is designed to develop a treatment that can be administered beginning 24 hours or longer after radiation exposure. NIH's National Institute of Allergy and Infectious Diseases is co-funding the pre-clinical studies for this project through its Radiation Nuclear Countermeasures Program.

Beta Thalassemia
The Development of Minihepcidins for the Treatment of Beta Thalassemia Brian MacDonald, Ph.D., president and CEO Merganser Biotech LLC, Newtown Square, Pa.

Patients with beta thalassemia, a rare inherited blood disorder, suffer from severe anemia and iron overload that can damage the heart. The disorder reduces production of hepcidin, the iron regulatory hormone. The goal of this project is to develop a treatment that increases levels of hepcidin and lowers the damaging effects of too much iron. NIH's National Institute of Diabetes and Digestive and Kidney Diseases is co-funding this project.

Cardiac Arrest-Induced Acute Brain Injury
HBN-1 Regulated Hypothermia Formulation and Evaluation of Toxicity Laurence Katz, M.D., associate professor of emergency medicine University of North Carolina at Chapel Hill

Patients resuscitated from cardiac arrest can suffer from acute brain injury. Lowering a patient's body temperature into therapeutic-induced hypothermia can improve survival with good neurological outcomes in more than half of patients who remain in a coma after cardiac arrest. This project is designed to develop HBN-1 as an intravenous treatment that paramedics can give to cardiac arrest patients to induce hypothermia sooner. The NIH Common Fund is funding the pre-clinical studies for this project.

"Although each project is selected for its scientific merit, not all projects will lead to treatments because the pre-clinical phase of drug development is fraught with failures related to issues such as adverse side effects," said John McKew, Ph.D., acting director of NCATS' Division of Pre-clinical Innovation and chief of the Therapeutics Development Branch. "Still, the support that BrIDGs provides gives each project a fighting chance."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Experimental Vaccine Protects Against Dengue Virus
An experimental dengue vaccine protected all the volunteers who received it from infection with a live dengue virus.
Wednesday, March 30, 2016
Promising Experimental Dengue Vaccine
A clinical trial in which volunteers were infected with dengue virus six months after receiving either an experimental dengue vaccine or a placebo injection yielded starkly contrasting results.
Thursday, March 17, 2016
Experimental Ebola Antibody Protects Monkeys
Antibody isolated from Ebola survivor can advance to clinical trials.
Friday, February 26, 2016
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Friday, February 05, 2016
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Friday, January 15, 2016
NIH Unveils FY2016–2020 Strategic Plan
Detailed plan sets course for advancing scientific discoveries and human health.
Thursday, December 17, 2015
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Tuesday, November 10, 2015
NIH Announces High-Risk, High-Reward Research Awardees
NIH to fund 78 awards to support highly innovative biomedical research.
Wednesday, October 07, 2015
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Thursday, August 27, 2015
Large Percentage of Youth with HIV May Lack Immunity to Measles, Mumps, Rubella
NIH study finds those vaccinated before starting modern HIV therapy may be at risk.
Tuesday, August 18, 2015
Scientific News
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
Biomarker Discovery Offers Hope For New TB Vaccine
A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!